TrialArthritis research & therapy2015

Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.

Marshelle S Warren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.